Beyond autophagic flux: selective autophagy adaptors and cargo prioritization in cardiac disease [0.03%]
超越自噬通量：心脏疾病中的选择性自噬适配器和货物优先级
Jenaro A Espitia-Corredor,Francisco Olivares-Silva,Constanza Alanis-Cubillos et al.
Jenaro A Espitia-Corredor et al.
Cardiovascular disease is the leading cause of death worldwide. Disrupted protein homeostasis contributes significantly to cardiomyocyte dysfunction and loss. While autophagy is recognized as a critical cardioprotective mechanism, most ther...
Histological validation of artificial intelligence-driven automatic plaque characterization in coronary OCT: a head-to-head comparison with clinicians [0.03%]
基于冠状动脉光学相干断层扫描的人工智能驱动的斑块特征自动分析的病理学验证及与临床医生的对比研究
Miao Chu,Francesca Razzi,Giovanni Luigi De Maria et al.
Miao Chu et al.
Background and purpose: Artificial intelligence (AI) is increasingly being applied to automate image interpretation, including in coronary optical coherence tomography (OCT), the gold standard for in vivo assessment of at...
Association between immune checkpoint inhibitors and adverse cardiovascular events in patients with coronary artery disease and malignant tumors: a retrospective cohort study [0.03%]
免疫检查点抑制剂与冠心病合并恶性肿瘤患者不良心血管事件的关联：一项回顾性队列研究
Ran Xu,Yan Wang,Qingqing Cai et al.
Ran Xu et al.
Background and purpose: With the widespread application of immune checkpoint inhibitors (ICIs) in cancer treatment, the associated risk of developing atherosclerotic cardiovascular injury is increasing. However, the risk ...
Advancing cardio-oncology: precision-guided cardiovascular care for oncology patients [0.03%]
推进肿瘤心脏病学：精确指导的肿瘤患者心血管护理
Jennifer E Liu
Jennifer E Liu
Cardio-oncology, an emerging subspecialty at the intersection of cardiology and oncology, addresses the growing cardiovascular burden among cancer patients and survivors. Advances in cancer therapies, including anthracyclines, immune checkp...
Coronary physiology in the catheterization laboratory: current practices, historical insights, and future directions [0.03%]
导管实验室中的冠状动脉生理学：当前实践、历史见解和未来方向
Simone Fezzi,Carlotta Rossignoli,Ludovica Guerrieri et al.
Simone Fezzi et al.
Coronary flow improvement and myocardial ischemia relief are the primary goals of coronary revascularization. The pioneering work of Andreas Gruntzig, who demonstrated the reduction of trans-stenotic pressure gradients following percutaneou...
RNA-ssisting immunity to heal the heart: a new frontier in therapeutics [0.03%]
用于心脏修复的免疫疗法新前沿：RNA助免疫疗法
Joel Gregory Rurik,Christian Le Phu,Julian Mustroph et al.
Joel Gregory Rurik et al.
Cardiovascular diseases remain the leading cause of death worldwide. Despite significant progress and the development of numerous effective drugs, substantial morbidity and mortality persist. This review highlights one potentially fruitful ...
Harnessing mRNA technology for ischemic heart disease: a review of regenerative and protective therapies [0.03%]
用于缺血性心脏病的mRNA技术再生和保护疗法综述
Matthew Adjmi,Isabelle Tse,Lior Zangi
Matthew Adjmi
As ischemic heart disease (IHD) remains the leading cause of mortality worldwide, there is an urgent need for innovative therapies that go beyond symptom management. The irreversible damage to cardiac tissue following myocardial infarction ...
Rats subject to extracorporeal membrane oxygenation have improved cardiac function following anticoagulation and reversal with factor IXa aptamer-antidote oligonucleotide pair [0.03%]
一种抗凝和逆转的因子IXa寡核苷酸.getApp对体外膜氧合大鼠心脏功能的影响
Shahid M Nimjee,Fellery de Lange,George A Pitoc et al.
Shahid M Nimjee et al.
Background and purpose: Unfractionated heparin (UFH) is the most commonly utilized rapid-onset anticoagulant, valued for its potency and reversibility with protamine. However, UFH and protamine are associated with signifi...
Retraction: Characteristics of patients undergoing percutaneous coronary intervention for chronically total occluded arteries: a single-center observational study in India [0.03%]
撤稿：印度单中心观察性研究中的经皮冠状动脉介入治疗慢性完全闭塞患者的特征
[This retracts the article DOI: 10.1097/CP9.0000000000000061.]. Copyright © 2024 China Heart House.
Retraction of Publication
Cardiology plus. 2024 Apr-Jun;9(2):156. DOI:10.1097/CP9.0000000000000082 2024
Pan-vascular disease: what we have done in the past and what we can do in the future? [0.03%]
泛血管疾病：过去和未来的展望
Mingjen Wong,Yuxiang Dai,Junbo Ge
Mingjen Wong